Can intravenous oxytocin infusion counteract hyperinflammation in COVID-19 infected patients?

Buemann B, Marazziti D, Uvnäs-Moberg K

World J Biol Psychiatry - (-) 1-12 [2020-09-11; online 2020-09-11]

Based on its well-documented anti-inflammatory and restorative properties we propose trials with the natural hormone oxytocin for treatment of hospitalised Covid-19 patients. We searched for, retrieved, and commented on specific literature regarding multiple functions of oxytocin with a special focus on its modulation of inflammatory, immune, and restorative functions. Available data gathered in animals and humans support the anti-inflammatory properties of oxytocin. The multiple anti-inflammatory effects of oxytocin have been demonstrated in vitro and in vivo in various animal models and also in humans in response to intravenous infusion of oxytocin. Furthermore, oxytocin has been documented to activate several types of protective and restorative mechanisms and to exert positive effects on the immune system. In addition, to being anti-inflammatory, it may be hypothesised, that oxytocin may be less suppressive on adaptive immune systems, as compared with glucocorticoids. Finally, by its restorative effects coupled with its anti-stress and healing properties, oxytocin may shorten the recovery period of the Covid-19 patients.

Type: Journal article

PubMed 32914674

DOI 10.1080/15622975.2020.1814408

Crossref 10.1080/15622975.2020.1814408


Publications 7.1.2